Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survival. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keyword...

Full description

Bibliographic Details
Main Authors:	Asiyeh Amouei, Nesa Daeian, Seyedeh Sana Khezrnia, Ava Mansouri, Molouk Hadjibabaie
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2021-04-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Imatinib mesylate; Treatment outcome; Antineoplastic agent resistance; Chronic myeloid leukemia; Adverse drug event
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1242

Similar Items

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)

Frequency of Hematological Response in Patients with Chronic Myeloid Leukemia (Chronic Phase) with Imatinib After Three Months Presenting to CMH Rawalpindi
by: Anil Babar, et al.
Published: (2024-04-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)

Subclinical Hypothyroidism Following Imatinib Use in Nigerian BCR::ABL1-positive Chronic Myeloid Leukemia Patients: A Prospective Cohort Study
by: Ibrahim Oluwaseun Ahmed, et al.
Published: (2024-09-01)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
by: Xiuyan Zhang, et al.
Published: (2023-10-01)

Molecular Monitoring of Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
by: Mehrdad Payandeh, et al.
Published: (2018-12-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

Aplasia irreversible por el tratamiento con mesilato de Imatinib en una leucemia mieloide crónica: Presentación de un caso Irreversible aplasia due to the treatment with imatinib mesilate in a chronic myeloid leukemia: A case report
by: Olga Agramonte Llanes, et al.
Published: (2007-04-01)

Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
by: Zhuan - Bo Luo, et al.
Published: (2017-11-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)

Histological changes of the rat liver after administration of imatinib mesylate:an experimental study
by: Luma Ibrahim Khalel Al-Allaf, et al.
Published: (2019-06-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate
by: Ismail Siti Mariam, et al.
Published: (2022-08-01)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
by: Kamran Moshfeghi, et al.
Published: (2013-01-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Reacciones adversas del imatinib como droga de segunda línea en pacientes con leucemia mieloide crónica Adverse reactions to imatinib as second-line drug in patients with chronic myeloid leukemia
by: Onel M. Ávila Cabrera, et al.
Published: (2010-12-01)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
by: Bassam Francis Matti, et al.
Published: (2013-12-01)

Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)

Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia
by: Arthur Gomes Oliveira Braga, et al.
Published: (2024-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis
by: Sicong Li, et al.
Published: (2022-11-01)

Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
by: Sylwester Głowacki, et al.
Published: (2021-04-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01)

Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China
by: Fang Cheng, et al.
Published: (2023-05-01)